Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Gains from Investment Securities (2016 - 2025)

Bio-Techne has reported Gains from Investment Securities over the past 17 years, most recently at $900000.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $900000.0 for Q4 2025, up 12.5% from a year ago — trailing twelve months through Dec 2025 was $900000.0 (up 12.5% YoY), and the annual figure for FY2025 was $1.8 million, up 56.48%.
  • Gains from Investment Securities for Q4 2025 was $900000.0 at Bio-Techne, roughly flat from $900000.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for TECH hit a ceiling of $232.0 million in Q1 2023 and a floor of -$26.7 million in Q2 2022.
  • Median Gains from Investment Securities over the past 5 years was $2.8 million (2022), compared with a mean of $28.2 million.
  • Biggest five-year swings in Gains from Investment Securities: plummeted 571.43% in 2021 and later surged 6723.53% in 2023.
  • Bio-Techne's Gains from Investment Securities stood at $25.0 million in 2021, then crashed by 90.8% to $2.3 million in 2022, then crashed by 43.48% to $1.3 million in 2023, then crashed by 38.46% to $800000.0 in 2024, then grew by 12.5% to $900000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $900000.0 (Q4 2025), $900000.0 (Q3 2025), and $30.6 million (Q2 2025) per Business Quant data.